NeuroMetrix, Inc. (Nasdaq: NURO) today reported that Michael MacDonald has been promoted to SVP and General Manager of Diagnostics. In this role, Mr. MacDonald will oversee the Company’s diagnostic products which include DPNCheck® and ADVANCE™.
MacDonald has been with NeuroMetrix for over 15 years, most recently as SVP of Commercial Operations. In this role, he has been responsible for the DPNCheck business in the Americas, Europe, Middle East and India. Prior roles included Vice President of Marketing, Vice President of Healthcare Economics, Director of Marketing and Region Sales Manager. Mr. MacDonald holds a B.S. degree in Business Administration from Northeastern University.
Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix said, “Diabetes is a world-wide epidemic that now affects over 300 million people. DPNCheck is a unique product with an important role in the early detection of diabetic neuropathy, which is most common long term complication of diabetes and the primary trigger for foot ulcers and lower limb amputations.” He concluded, “Under Mike’s leadership we have built our DPNCheck business to include a robust Medicare Advantage business in the U.S., growing sales in Mexico, and emerging opportunities in the Middle East and other markets. These opportunities complement our partnership with Omron Healthcare in Japan and China. In this expanded role, Mike will become involved in all aspects of our DPNCheck business as well as continue to manage our legacy ADVANCE diagnostics business.”